Director’s Share Dealings

SHIRE PLC - Director’s Share Dealings

PR Newswire

London, May 3

Director's Share Dealings

May 3, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that, following theappointment of Flemming Ornskov, MD, to the Board of Shire plc as ChiefExecutive Officer Designate on January 2, 2013 and in accordance with the termsof his employment agreement, on May 2, 2013 Dr. Ornskov was conditionallygranted 15,286 deferred American Depository Shares ("ADSs") and a replacementequity award under the Shire Portfolio Share Plan over 29,805 ADSs.

The deferred ADSs represent approximately 75% of the replacement payment paidto Dr. Ornskov as compensation for the sign-on bonus and annual bonus heforfeited in connection with the termination of his prior employment. TheseADSs will be released on February 28, 2015, the second anniversary of theoriginally planned date of grant of February 28, 2013, subject to Dr. Ornskov'scontinued employment at the date of vesting.

Dr. Ornskov's replacement equity award comprises Stock Appreciation Rights("SARs") over 18,984 ADSs at an exercise price of $91.59 per ADS andPerformance Share Awards ("PSAs") over 10,821 ADSs. The SARs and PSAs willnormally vest on the third anniversary of the date of grant, subject toperformance targets being satisfied. No consideration was paid for the grant ofSARs and PSAs.

Following this transaction, Dr. Ornskov holds awards of SARs, PSAs and deferredshares over 124,893 ADSs. One ADS is equal to three Shire ordinary shares of 5pence each.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)of the Disclosure and Transparency Rules.

For further information please contact:

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,Internal Medicine and Regenerative Medicine and we are developing treatmentsfor symptomatic conditions treated by specialist physicians in other targetedtherapeutic areas.

www.shire.com